This report clearly shows that the driver of exploding RX costs is the branded single source pharmaceuticals.A number of years back when I was employed by the Sandoz division of Novartis, we were told that they were developing a robust pipeline of drugs known as a Bio-similar drugs.
This pipeline has not come to market here in the United States due to regulatory and legal issues. In my opinion, these products could help to contain the RX inflation that is a major factor in the rising cost of our health insurance today.
Read more from Blue Cross Blue Shield here:
